

Tick-borne Encephalitis: Course and Complications – Our Observations from 2009 to 2012

Klíšťová encefalitida, průběh a komplikace – naše poznatky z let 2009–2012

Abstract

Objective: Description of the course, complications and permanent sequelae of tick-borne encephalitis in patients hospitalized at the Department of Infectious Diseases of the Faculty of Medicine, Masaryk University and University Hospital Brno. **Patients and methods:** Prospective monitoring of epidemiological, clinical and laboratory data of 107 patients diagnosed with tick-borne encephalitis (TBE) and hospitalized between 2009 and 2012. **Results:** The study set comprised 107 patients. The disease presented as meningitis in 50 patients, meningoencephalitis in 45 patients, and meningoencephalomyelitis in 12 patients (46.7%, 42.1% and 11.2%, respectively). Paresis developed in 14 patients. Permanent paresis was observed in 5.6% of patients. Two patients died of the disease (lethality 1.9%). Ninety seven patients completed six-month follow-up and 90 patients 12-month follow-up after discharge from the hospital. More than one third of patients presented with symptoms of post-encephalitic syndrome one year after the acute phase of the disease subsided. Concomitant Lyme disease was recorded in 12 patients (11.2%). A statistically significant difference was not found between single and dual infections in severity of the disease and its complications. **Conclusion:** Even when its course is uncomplicated, TBE requires several weeks of convalescence. Paresis frequently has permanent sequelae. Following the acute phase of the disease, more than one-third of patients has long-term complaints associated with the post-encephalitic syndrome that significantly affect their quality of life. The risk of complications increases with age.

Souhrn

Cíl práce: Popsat průběh, komplikace a riziko trvalých následků klíšťové encefalitidy u pacientů hospitalizovaných na Klinice infekčních chorob LF MU a FN Brno. **Soubor a metodika:** Prospektivní sledování epidemiologických, klinických a laboratorních dat u 107 pacientů s diagnostikovanou klíšťovou encefalitidou hospitalizovaných v letech 2009–2012. **Výsledky:** Do souboru bylo zařazeno celkem 107 pacientů. Onemocnění probíhalo pod obrazem meningitidy u 50 (46,7 %), meningoencefalitidy u 45 (42,1 %) a meningoencefalomyelitidy u 12 pacientů (11,2 %). Parézy se rozvinuly u 14 pacientů. Trvalé parétycké postižení bylo pozorováno u 5,6 %. U dvou pacientů skončilo onemocnění úmrtím (letalita 1,9 %). K dalšímu sledování po propuštění se dostavilo s odstupem šesti měsíců 97 pacientů, po jednom roce 90 pacientů. Projevy postencefalitického syndromu měla rok od odeznění akutních potíží více než třetina nemocných. Současné onemocnění Lymeskou nemocí bylo prokázáno u 12 pacientů (11,2 %). Nebyl prokázán statisticky signifikantní rozdíl mezi pacienty s izolovanou a kombinovanou infekcí, co se týče tíže onemocnění a výskytu komplikací. **Závěr:** I nekomplikovaný průběh KE vyžaduje několikátýdenní rekonvalescenci. Pokud dojde k parétyckému postižení, jsou následky mnohdy trvalé. U více než třetiny pacientů obtíže v rámci postencefalitického syndromu přetrvávají dlouhodobě po odeznění akutního onemocnění a významně ovlivňují následnou kvalitu života. Riziko komplikací narůstá s věkem.

Supported by the Ministry of Health, Czech Republic – conceptual development of research organization (FNBr, 65269705).

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy. The Editorial Board declares that the manuscript met the ICMJE "uniform requirements" for biomedical papers. Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

M. Pychova¹, J. Strakova², P. Husa¹

¹ Department of Infectious Diseases, Faculty of Medicine, Masaryk University and University Hospital Brno

² Department of Nursing, Faculty of Medicine, Masaryk University



Martina Pychova, MD
Department of Infectious Diseases, Faculty of Medicine
Masaryk University and University Hospital Brno
Jihlavská 20
625 00 Brno
e-mail:
martina.pychova@fnbrno.cz

Accepted for review: 15. 8. 2013
Accepted for print: 31. 10. 2013

Key words

tick-borne encephalitis – post-encephalitic syndrome

Klíčová slova

klíšťová encefalitida – postencefalitický syndrom

Introduction

Tick-borne encephalitis (TBE) is a viral disease affecting the nervous system. Approximately 3,000 cases are reported in Europe annually. The highest incidence is in Russia. The Czech Republic takes the second place with its 500–800 annual cases [1]. A virus belonging to the *Flaviviridae* family is the causative agent of the disease. It is a naked RNA virus, 20–50 nm in size. The disease affects a broad region reaching from the Central Europe to the Far East. There are three viral subtypes – European, Siberian, and Far-Eastern subtype [2–4].

Just like in other *Flaviviridae*, transmission is via a blood-sucking vector. In the Czech Republic, this is the sheep-tick (*Ixodes ricinus*). The virus is contained in the tick's salivary glands and its transmission commences at the first instances of sucking. Small mammals, particularly rodents, are the natural source of the virus. Humans and other mammals (goats, cows, sheep) are incidental hosts [2]. An infrequent but possible transmission pathway involves ingestion of non-pasteurized milk of infected animals (mostly goat and sheep) or products made from such milk [2,3]. The clinical picture of the disease was first described in 1930s, when an Austrian doctor Schneider described seasonality of the occurrence of aseptic meningitis [4]. Incubation period of the disease is 2–28 days. Just as in other arboviral diseases, course of the disease is mostly asymptomatic. Symptomatic phase, however, follows typical biphasic course in two thirds of patients. The first, so-called febrile phase of the disease, characterized by flu-like symptoms, is a manifestation of viraemia. A period of 2–10 days of temporary improvement follows. The second phase of the disease then commences, characterized by development of neurological symptoms [5,6]. There are several forms of the disease, depending on the type of neural involvement – meningitis (approx. 50% of patients), encephalitis (40%) and meningoencephalomyelitis (10%); the most serious bulbar form affects the brain stem. It is typical for tick-borne encephalitis that pareses can develop as late as 5–10 days after the febrile stage [7,8]. Development of so called post-encephalitic syndrome, a collection of reversible non-specific neuropsychiatric complaints resulting from nervous system

inflammation (cephalea, fatigue, sleep disturbances, emotional lability etc.) represent another possible complication that may last for years [9]. TBE diagnostics is based on clinical examination, history of tick bite, inflammatory changes in the cerebrospinal fluid (CSF) (tens to hundreds of predominantly polynuclear cells) and the presence of specific antibodies in the serum [10]. TBE therapy is symptomatic, there is no causal medication available so far. Application of a specific immunoglobulin has also been previously tested. However, the effect of this treatment was questionable; clinical condition of six children worsened after the application [6,7,11]. TBE is, however, preventable by vaccination. An effective vaccine has been available since 1970s. Currently, two vaccines are available on the Czech market, both also in a pediatric form [12]. Vaccine manufacturers claim higher than 98% efficacy of the vaccines [13]. Preventive vaccination should be recommended mainly to older persons living in endemic areas as well as to persons with higher occupational risk, such as those employed in agriculture and forestry (125 cases of occupational TBE infections have been recorded in the Czech Republic between 1994 and 2009) [14].

Patients and methods

Patients diagnosed with TBE and hospitalized at the Department of Infectious Diseases at the University Hospital (UH) in Brno between 2009 and 2012, were included. Data were collected between May 2009 and June 2012. According to clinical symptoms, course of the disease was classified as meningitis (fever, cephalgia, pleocytosis in the cerebrospinal fluid, nausea, photophobia), meningoencephalitis (concurrent tremor, ataxia, qualitative or quantitative disturbance of consciousness) and meningoencephalomyelitis (development of flaccid pareses). Patients were monitored both during hospitalization and in the course of three follow-ups scheduled throughout the following year. Patient participation was voluntary. The follow-ups were scheduled at 1, 6 and 12 months after discharge from the hospital. Presence of the following subjective complaints was evaluated: headache, fatigue, vertigo, and sleep, memory and concentration disturbances. Paresis, basic neurological examination including EEG, duration of persis-

tence of TBE-specific IgM antibodies in the serum and detection of concomitant Lyme disease (defined by the presence of erythema migrans or fulfilling diagnostic criteria for neuroborreliosis) were also assessed [15]. The parameters were recorded in a recording sheet. Collected data were evaluated using the STATISTIKA CZ software, version 10, and Microsoft Excel. Correlation between complications (development of pareses, impaired consciousness, death) and concomitant presence of Lyme disease was tested by the Pearson χ^2 test at a significance level of 0.05. Given the sample size, distribution of quantitative variables (age, duration of hospitalization) was considered parametric.

Results

The study sample included 107 patients. Their mean age was 45.6 years (median 47.0 and standard deviation (SD) 16.1). The youngest was 18 (patients 18 years old and older only are hospitalized at the Department of Infectious Diseases, UH Brno) and the oldest was 88 years of age. 41.1% of the monitored patients were females, 58.9% were males. 28% of patients did not notice a tick bite prior to the illness. Possibility of alimentary acquisition of the disease (via a home-made sheep's milk cheese) was considered in one female patient. The most frequently reported incubation period was 3–8 days (27.1%). 21% of patients did not observe biphasic course. Meningitis symptoms appeared in 50 patients, meningoencephalitis in 45 patients, and meningoencephalomyelitis in 12 patients (46.7%, 42.1% and 11.2%, respectively). Mean duration of hospitalization was 14.3 days (median 14.0, SD 16.1, range 7–49 days). Patients with impaired consciousness were hospitalized for the mean of 15.7 days (median 15.0, SD, 3.2, range 9–22 days) and patients with paretic complications for the mean of 16.3 days (median 16.0, SD 4.8, range 9–30 days). A combination of impaired consciousness and paresis was identified in 6.5% of patients. Tab. 1 lists the different types of paretic complications (three patients had a combination of two types of paresis) and Tab. 2 their duration (two patients died during hospitalization). Clinical condition of two patients (44- and 51-year-old-men with no previous co-morbidities) was complicated as they developed the bulbar form of the

disease, necessitating vital function support (mechanical ventilation, temporary external ventricular stimulation), and paretic complications (triparesis and quadriparesis). Both cases were lethal (cause of death was bronchopneumonia). Concomitant Lyme disease was diagnosed in 12 patients. Two patients had typical erythema migrans (both had meningoencephalitis), 10 patients had neuroborreliosis (nine meningitis, one meningoencephalitis). Patient with meningoencephalitis had a combination of paresis (cranial nerves) and qualitative consciousness disturbance. One patient was admitted again three weeks after discharge because of gradual development of lower limb paraparesis. Neuroborreliosis was diagnosed (during the first examination, the patient had positive serology in the blood only, second examination revealed intrathecal production of specific antibodies). There also were another 11 patients with suspected neuroborreliosis (CFS pleocytosis and neurological symptoms with positive serology in the blood but no intrathecal production of anti-borrelial antibodies). Follow-up monitoring after discharge had a form of voluntary ambulatory examinations over one year. One month after discharge, 33/105 patients (30.8%) had abnormal EEG; EEG results were not documented in three patients. Tab. 3 presents selected symptoms of post-encephalitic syndrome six and twelve months after discharge. For various reasons, only 97 of 107 patients completed the 6-month follow-up and 90 patients completed 12-month follow-up after discharge from the hospital. Specific IgM class of anti-TBE antibodies were found in 36 patients (41.4%) one year after discharge.

Discussion

The majority of our patients presented with meningitis (46.7%). This correlates with the results of similar prospective studies by Günther (55%) and Kaiser (49%) [16,17]. The typical biphasic course of the disease was observed in 2/3 of our patients only, and up to 1/3 of patients did not notice a tick bite. Paresis was observed in all meningoencephalomyelitis patients (12) and in two patients with meningoencephalitis (two patients with a paresis of a cranial nerve (one with concomitant neuroborreliosis), one patient with hemiparesis – 4.5% of

Tab. 1. Forms of paretic affection.

| Paresis type | Number |
|----------------------------|--------|
| paresis of brachial plexus | 5 |
| paresis of lower limb | 1 |
| paresis of cranial nerves | 5 |
| hemiparesis | 1 |
| paraparesis | 1 |
| triparesis | 1 |
| quadriparesis | 3 |
| combined pareses | 3 |

patients with meningoencephalitis). Similar to our results (5.6%), Mickiene and Kaiser reported permanent residual paresis in 2.6–7% of respondents. In affected patients, and these are predominantly middle-aged and older, neurological deficit is likely to be permanent. Lethality in our patient sample was 1.9%, corresponding to the available data for the European subtype of the virus [5,18]. Both deceased patients were middle-aged. Approximately one tenth of patients (11.2%) were diagnosed with definitive Lyme disease. We did not identify any statistically significant correlation between selected TBE complications and concomitant Lyme disease ($p = 0.87$ for pareses, $p = 0.25$ for impaired consciousness). Also, no patient with concomitant borreliosis died. A group of Finnish authors reported a fatal case of TBE with concomitant borreliosis [19]. Each our patient with definite Lyme disease or possible borreliosis was treated with antibiotics [15,20]. We also monitored post-encephalitic syndrome. In their prospective studies focusing on the course and complications of

Tab. 2. Duration of paretic affection.

| Duration | Number of cases |
|--------------------------|-----------------|
| Up to hospital discharge | 3 |
| < 6 months | 2 |
| 6–12 months | 1 |
| > 12 months | 6 |

TBE, Smiskova and Günther reported on prolonged symptoms of post-encephalitic syndrome in approximately one-third of their patients; this is in line with our findings (39.6%) [8,16,17]. Post-encephalitic syndrome is observed more often in TBE than other viral neuroinfections [16].

Conclusion

Uncomplicated clinical course of TBE requires several weeks of convalescence. Paresis frequently has permanent sequelae. Development of post-encephalitic syndrome also significantly affects quality of life in the horizon of many months or years after infection. Our results suggest that, after the acute illness, approximately one third of patients has long-term complaints, and their subsequent quality of life is significantly altered. The risk of complications increases with age. There is no causal therapy. It is, however, a vaccine-preventable disease. Despite this, less than 20% of the Czech Republic population have been vaccinated.

References

1. Kunze U. Tick-borne encephalitis (TBE): An underestimated risk...still: Report of the 14th Annual Meeting of the International Scientific Working Group

Tab. 3. Post-encephalitic syndrome – monitored manifestations.

| Manifestation | After six months | | After one year | |
|----------------------------|------------------|------|----------------|------|
| | (n = 97) | (%) | (n = 90) | (%) |
| headaches | 42 | 43.3 | 30 | 33.3 |
| fatigue | 35 | 32.7 | 17 | 18.9 |
| sleep disturbances | 17 | 17.5 | 10 | 11.1 |
| vertigo | 6 | 6.2 | 2 | 2.2 |
| memory disturbances | 9 | 9.3 | 13 | 13.7 |
| concentration disturbances | 8 | 8.3 | 3 | 3.3 |

on Tick-Borne Encephalitis (ISW-TBE). *Ticks Tick Borne Dis* 2012; 3(3): 197–201.

2. Dobler G, Gniel D, Petermann R, Pfeffer M. Epidemiology and distribution of tick-borne encephalitis. *Wien Med Wochenschr* 2012; 162(11–12): 230–238.
3. Cisak E, Wójcik-Fatla A, Zajac V, Sroka J, Buczek A, Dutkiewicz J. Prevalence of tick-borne encephalitis virus (TBEV) in samples of raw milk taken randomly from cows, goats and sheep in eastern Poland. *Ann Agric Environ Med AAEM* 2010; 17(2): 283–286.
4. Dumpis U, Crook D, Oksi J. Tick-borne encephalitis. *Clin Infect Dis* 1999; 28(4): 882–890.
5. Bogovic P, Lotric-Furlan S, Strle F. What tick-borne encephalitis may look like: clinical signs and symptoms. *Travel Med Infect Dis* 2010; 8(4): 246–250.
6. Lindquist L, Vapalahti O. Tick-borne encephalitis. *Lancet* 2008; 371(9627): 1861–1871.
7. Mansfield KL, Johnson N, Phipps LP, Stephenson JR, Fooks AR, Solomon T. Tick-borne encephalitis virus – a review of an emerging zoonosis. *J Gen Virol* 2009; 90(8): 1781–1794.
8. Smišková D, Polívková S, Blechová Z, Marešová V. Klíšťová meningoencefalitída, klinický průběh a komplikace. *Vakcinologie* 2010; 4(3): 106–109.
9. Pícha D. Infekce nervové soustavy. In: Bednařík J, Ambler Z, Růžička E (eds). *Klinická neurologie část speciální*. 1st ed. Praha: Triton 2010.
10. Holzmann H. Diagnosis of tick-borne encephalitis. *Vaccine* 2003; 21 (Suppl 1): S36–S40.
11. Waldvogel K, Bossart W, Huisman T, Boltshauser E, Nadal D. Severe tick-borne encephalitis following passive immunization. *Eur J Pediatr* 1996; 155(9): 775–779.
12. Zent O, Bröker M. Tick-borne encephalitis vaccines: past and present. *Expert Rev Vaccines* 2005; 4(5): 747–755.
13. Heinz FX, Holzmann H, Essl A, Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. *Vaccine* 2007; 25(43): 7559–7567.
14. Fenclová Z, Urban P, Pelclová D, Navrátil T. Neurologická profesionální onemocnění v České republice v letech 1994–2009. *Cesk Slov Neurol N* 2012; 75/108(1): 70–74.
15. Myglund A, Ljøstad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I et al. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. *Eur J Neurol Off J Eur Fed Neurol Soc* 2010; 17(1): 8–16.
16. Günther G, Haglund M, Lindquist L, Forsgren M, Sköldenberg B. Tick-borne encephalitis in Sweden in relation to aseptic meningo-encephalitis of other etiology: a prospective study of clinical course and outcome. *J Neurol* 1997; 244(4): 230–238.
17. Kaiser R. The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994–98: a prospective study of 656 patients. *Brain J Neurol* 1999; 122(11): 2067–2078.
18. Mickiene A, Laiskonis A, Günther G, Vene S, Lundkvist A, Lindquist L. Tick-borne encephalitis in an area of high endemicity in Lithuania: disease severity and long-term prognosis. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2002; 35(6): 650–658.
19. Oksi J, Viljanen MK, Kalimo H, Peltonen R, Marttía R, Salomaa P et al. Fatal encephalitis caused by concomitant infection with tick-borne encephalitis virus and *Borrelia burgdorferi*. *Clin Infect Dis Off Publ Infect Dis Soc Am* 1993; 16(3): 392–396.
20. Dlouhý P, Honegr K, Krbková L, Pícha D, Roháčová H, Štruncová V. Lymeská borrelióza – doporučený postup v diagnostice, léčbě a prevenci. *Klin Mikrobiol Infekční Lékařství* 2011; 17(4): 144–153.

Mezinárodní sympozium Trends in Neurophysiology of Movement Disorders and Multiple Sclerosis

15.–16. 10. 2014

www.trends-neurophysiol2014.upol.cz

61. společný sjezd české a slovenské společnosti pro klinickou neurofyzilogii

17.–18. 10. 2014

www.czech-slovakneurophysiol2014.upol.cz

Organizační zajištění:

Konferenční servis, Univerzita Palackého v Olomouci,
Biskupské nám. 1, 771 11 Olomouc

